Various efforts have been made to improve the performances of preoperative US-FNAB [1], [7], [9], including measurement of tumor markers used in the management of breast cancer patients such as CEA and CA 15-3 from US-FNAB aspirates [7]. This evidence concerns the gene CEACAM5 and breast carcinoma.